Long Term Open Label Continuation Study

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Abbott
Study ID
NCT00195650
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — BIOLOGICAL
    Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)

Study Details

The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.

Key Dates

Start date
Jul 31, 2000
Status verified
Aug 2012
Primary completion
May 31, 2011
Completion
May 31, 2011

Study Design

Enrollment
846 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Adalimumab
    Open-label adalimumab 40 mg

Primary Outcome Measure

Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520 [ Time Frame: Week 520 ]

Locations (74)

FacilityCityStateZIPSite coordinators
Site Reference ID/Investigator# 4111BirminghamAlabama35294-7201-
Site Reference ID/Investigator# 538BirminghamAlabama35205-
Site Reference ID/Investigator# 4113MobileAlabama36608-
Site Reference ID/Investigator# 408AnchorageAlaska99508-
Site Reference ID/Investigator# 537TucsonArizona85710-
Site Reference ID/Investigator# 66822AnaheimCalifornia92801-
Site Reference ID/Investigator# 557La JollaCalifornia92037-0943-
Site Reference ID/Investigator# 387Los AngelesCalifornia90048-
Site Reference ID/Investigator# 555Los AngelesCalifornia90095-
Site Reference ID/Investigator# 552Santa BarbaraCalifornia93105-
Site Reference ID/Investigator# 66864Santa MonicaCalifornia90404-
Site Reference ID/Investigator# 535StanfordCalifornia94305-
Site Reference ID/Investigator# 3412UplandCalifornia91786-
Site Reference ID/Investigator# 451Westlake VillageCalifornia91361-
Site Reference ID/Investigator# 572Colorado SpringsColorado80910-
Site Reference ID/Investigator# 4109DenverColorado80230-
Site Reference ID/Investigator# 541DanburyConnecticut06810-
Site Reference ID/Investigator# 654MilfordConnecticut06460-
Site Reference ID/Investigator# 655WilmingtonDelaware19808-
Site Reference ID/Investigator# 455Daytona BeachFlorida32114-
Site Reference ID/Investigator# 431Fort LauderdaleFlorida33334-
Site Reference ID/Investigator# 574Fort MyersFlorida33901-
Site Reference ID/Investigator# 66843GainesvilleFlorida32605-
Site Reference ID/Investigator# 579OrlandoFlorida32804-
Site Reference ID/Investigator# 571Palm HarborFlorida34684-
Site Reference ID/Investigator# 651SarasotaFlorida34239-
Site Reference ID/Investigator# 66863St. PetersburgFlorida33710-
Site Reference ID/Investigator# 542TampaFlorida33609-
Site Reference ID/Investigator# 415Vero BeachFlorida32962-
Site Reference ID/Investigator# 652ZephyrhillsFlorida33542-
Site Reference ID/Investigator# 4110BoiseIdaho83706-
Site Reference ID/Investigator# 449BoiseIdaho83702-
Site Reference ID/Investigator# 650Coeur d'AleneIdaho83814-
Site Reference ID/Investigator# 578ChicagoIllinois60612-
Site Reference ID/Investigator# 4112IndianapolisIndiana46260-
Site Reference ID/Investigator# 547LouisvilleKentucky40291-
Site Reference ID/Investigator# 534MetairieLouisiana70006-
Site Reference ID/Investigator# 544Chevy ChaseMaryland20815-
Site Reference ID/Investigator# 653BostonMassachusetts02115-
Site Reference ID/Investigator# 4114WorcesterMassachusetts01610-
Site Reference ID/Investigator# 546PetoskeyMichigan49770-
Site Reference ID/Investigator# 577St LouisMissouri63128-
Site Reference ID/Investigator# 549BillingsMontana59101-
Site Reference ID/Investigator# 561RenoNevada89502-
Site Reference ID/Investigator# 573DoverNew Jersey07801-
Site Reference ID/Investigator# 66842Toms RiverNew Jersey08755-
Site Reference ID/Investigator# 559Voorhees TownshipNew Jersey08043-
Site Reference ID/Investigator# 562AlbuquerqueNew Mexico87102-
Site Reference ID/Investigator# 66823BrooklynNew York11203-
Site Reference ID/Investigator# 432Lake SuccessNew York11042-
Site Reference ID/Investigator# 647New YorkNew York10021-
Site Reference ID/Investigator# 657New YorkNew York10003-
Site Reference ID/Investigator# 545Port Jefferson StationNew York11776-
Site Reference ID/Investigator# 540SyracuseNew York13210-
Site Reference ID/Investigator# 646StatesvilleNorth Carolina28625-
Site Reference ID/Investigator# 438CincinnatiOhio45219-
Site Reference ID/Investigator# 436DaytonOhio45408-
Site Reference ID/Investigator# 548BendOregon97701-
Site Reference ID/Investigator# 553EugeneOregon97401-
Site Reference ID/Investigator# 532PortlandOregon97205-
Site Reference ID/Investigator# 570BethlehemPennsylvania18015-
Site Reference ID/Investigator# 575Ridley ParkPennsylvania19078-2210-
Site Reference ID/Investigator# 585Willow GrovePennsylvania19090-
Site Reference ID/Investigator# 2435DallasTexas75231-
Site Reference ID/Investigator# 536RichmondVirginia23219-
Site Reference ID/Investigator# 649EverettWashington98201-
Site Reference ID/Investigator# 66862EverettWashington98201-
Site Reference ID/Investigator# 531KirklandWashington98034-
Site Reference ID/Investigator# 412OlympiaWashington98502-
Site Reference ID/Investigator# 658SpokaneWashington99204-
Site Reference ID/Investigator# 576VancouverWashington98664-
Site Reference ID/Investigator# 551YakimaWashington98902-
Site Reference ID/Investigator# 656GlendaleWisconsin53217-
Site Reference ID/Investigator# 539MilwaukeeWisconsin53215-

Find similar trials in Birmingham, AL

By condition
Rheumatoid arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
Site Reference ID/Investigator# 4111· Birmingham, ALSite Reference ID/Investigator# 538· Birmingham, ALSite Reference ID/Investigator# 4113· Mobile, ALSite Reference ID/Investigator# 408· Anchorage, AKSite Reference ID/Investigator# 537· Tucson, AZSite Reference ID/Investigator# 66822· Anaheim, CA

Related Studies